218 related articles for article (PubMed ID: 29903912)
1. Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.
Kummarapurugu AB; Afosah DK; Sankaranarayanan NV; Navaz Gangji R; Zheng S; Kennedy T; Rubin BK; Voynow JA; Desai UR
J Biol Chem; 2018 Aug; 293(32):12480-12490. PubMed ID: 29903912
[TBL] [Abstract][Full Text] [Related]
2. 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.
Griffin KL; Fischer BM; Kummarapurugu AB; Zheng S; Kennedy TP; Rao NV; Foster WM; Voynow JA
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):684-9. PubMed ID: 24325600
[TBL] [Abstract][Full Text] [Related]
3. Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.
Kummarapurugu AB; Zheng S; Pulsipher A; Savage JR; Ma J; Rubin BK; Kennedy TP; Voynow JA
Am J Respir Cell Mol Biol; 2021 Feb; 64(2):260-267. PubMed ID: 33264072
[TBL] [Abstract][Full Text] [Related]
4. On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.
Morla S; Sankaranarayanan NV; Afosah DK; Kumar M; Kummarapurugu AB; Voynow JA; Desai UR
J Med Chem; 2019 Jun; 62(11):5501-5511. PubMed ID: 31074986
[TBL] [Abstract][Full Text] [Related]
5. Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.
Voynow JA; Zheng S; Kummarapurugu AB
Front Pharmacol; 2020; 11():1011. PubMed ID: 32733248
[TBL] [Abstract][Full Text] [Related]
6. 2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage function.
Wang M; Gauthier AG; Kennedy TP; Wang H; Velagapudi UK; Talele TT; Lin M; Wu J; Daley L; Yang X; Patel V; Mun SS; Ashby CR; Mantell LL
Mol Med; 2021 Jul; 27(1):79. PubMed ID: 34271850
[TBL] [Abstract][Full Text] [Related]
7. 2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box 1 Release by Inhibition of p300 Acetyltransferase Activity.
Zheng S; Kummarapurugu AB; Afosah DK; Sankaranarayanan NV; Boothello RS; Desai UR; Kennedy T; Voynow JA
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):90-98. PubMed ID: 27585400
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors.
Schuster A; Fahy JV; Ueki I; Nadel JA
Eur Respir J; 1995 Jan; 8(1):10-4. PubMed ID: 7744174
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy.
Papayannopoulos V; Staab D; Zychlinsky A
PLoS One; 2011; 6(12):e28526. PubMed ID: 22174830
[TBL] [Abstract][Full Text] [Related]
10. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
Guyot N; Butler MW; McNally P; Weldon S; Greene CM; Levine RL; O'Neill SJ; Taggart CC; McElvaney NG
J Biol Chem; 2008 Nov; 283(47):32377-85. PubMed ID: 18799464
[TBL] [Abstract][Full Text] [Related]
11. Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis sputum: inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands.
Schuster A; Hansen G; Zubrod-Eichert C; Wahn V
Pediatr Res; 1996 Nov; 40(5):732-7. PubMed ID: 8910939
[TBL] [Abstract][Full Text] [Related]
12. A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation.
Chillappagari S; Müller C; Mahavadi P; Guenther A; Nährlich L; Rosenblum J; Rubin BK; Henke MO
J Cyst Fibros; 2016 May; 15(3):325-31. PubMed ID: 26526358
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques.
Oriano M; Terranova L; Sotgiu G; Saderi L; Bellofiore A; Retucci M; Marotta C; Gramegna A; Miglietta D; Carnini C; Marchisio P; Chalmers JD; Aliberti S; Blasi F
Pulm Pharmacol Ther; 2019 Dec; 59():101856. PubMed ID: 31626976
[TBL] [Abstract][Full Text] [Related]
14. Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions.
Hentschel J; Fischer N; Janhsen WK; Markert UR; Lehmann T; Sonnemann J; Böer K; Pfister W; Hipler UC; Mainz JG
J Cyst Fibros; 2015 May; 14(3):324-33. PubMed ID: 25286826
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of neutrophil elastase in CF sputum by L-658,758.
Rees DD; Brain JD; Wohl ME; Humes JL; Mumford RA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1201-6. PubMed ID: 9399994
[TBL] [Abstract][Full Text] [Related]
16. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.
Barth P; Bruijnzeel P; Wach A; Sellier Kessler O; Hooftman L; Zimmermann J; Naue N; Huber B; Heimbeck I; Kappeler D; Timmer W; Chevalier E
J Cyst Fibros; 2020 Mar; 19(2):299-304. PubMed ID: 31501052
[TBL] [Abstract][Full Text] [Related]
17. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.
Gehrig S; Duerr J; Weitnauer M; Wagner CJ; Graeber SY; Schatterny J; Hirtz S; Belaaouaj A; Dalpke AH; Schultz C; Mall MA
Am J Respir Crit Care Med; 2014 May; 189(9):1082-92. PubMed ID: 24678594
[TBL] [Abstract][Full Text] [Related]
18. Targeting neutrophil elastase in cystic fibrosis.
Kelly E; Greene CM; McElvaney NG
Expert Opin Ther Targets; 2008 Feb; 12(2):145-57. PubMed ID: 18208364
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
20. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy.
Meyer KC; Lewandoski JR; Zimmerman JJ; Nunley D; Calhoun WJ; Dopico GA
Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):580-5. PubMed ID: 1892298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
